• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Introduction to N-methyl-1-3-(1H-pyrazol-1-yl)phenylmethanamine Hydrochloride (CAS No. 956533-47-4)

N-methyl-1-3-(1H-pyrazol-1-yl)phenylmethanamine Hydrochloride, a compound with the chemical identifier CAS No. 956533-47-4, represents a significant advancement in the field of pharmaceutical chemistry. This compound, characterized by its complex molecular structure, has garnered considerable attention due to its potential applications in medicinal chemistry and drug development. The hydrochloride salt form of this molecule enhances its solubility and bioavailability, making it a promising candidate for further investigation in therapeutic contexts.

The molecular framework of N-methyl-1-3-(1H-pyrazol-1-yl)phenylmethanamine Hydrochloride incorporates several key functional groups that contribute to its unique chemical properties. The presence of a pyrazole ring, a well-known pharmacophore in medicinal chemistry, suggests potential interactions with biological targets such as enzymes and receptors. Additionally, the phenylmethanamine moiety introduces an amine group that can engage in hydrogen bonding, further influencing its pharmacological profile.

Recent research in the field of drug discovery has highlighted the importance of heterocyclic compounds in developing novel therapeutic agents. Pyrazole derivatives, in particular, have shown promise in various therapeutic areas, including anti-inflammatory, anti-viral, and anticancer applications. The structural features of N-methyl-1-3-(1H-pyrazol-1-yl)phenylmethanamine Hydrochloride align well with these trends, positioning it as a valuable compound for further exploration.

In vitro studies have begun to elucidate the pharmacological properties of this compound. Initial experiments suggest that it exhibits moderate affinity for certain biological targets, making it a potential lead compound for further optimization. The hydrochloride salt form has been found to improve the compound's solubility in aqueous solutions, which is crucial for formulation development and clinical trials.

The synthesis of N-methyl-1-3-(1H-pyrazol-1-yl)phenylmethanamine Hydrochloride involves multi-step organic reactions that require precise control over reaction conditions. Advanced synthetic methodologies have been employed to ensure high yield and purity, which are essential for pharmaceutical applications. The use of chiral auxiliaries and catalysts has been explored to enhance the enantioselectivity of the synthesis, which is critical for developing enantiomerically pure drugs.

One of the most intriguing aspects of this compound is its potential role in modulating biological pathways associated with disease progression. For instance, studies have indicated that pyrazole derivatives can interfere with key enzymatic processes involved in inflammation and cancer cell proliferation. The amine group in N-methyl-1-3-(1H-pyrazol-1-yl)phenylmethanamine Hydrochloride may also contribute to its ability to interact with protein targets, offering a dual mechanism of action.

As research continues to evolve, the applications of N-methyl-1-3-(1H-pyrazol-1-yl)phenylmethanamine Hydrochloride are expected to expand. Collaborative efforts between academic researchers and pharmaceutical companies are likely to drive innovation in this area. Preclinical studies are currently underway to evaluate its safety profile and efficacy in animal models, which could pave the way for human clinical trials.

The development of new drugs is a complex process that requires meticulous evaluation at multiple stages. N-methyl-1-3-(1H-pyrazol-1-yl)phenylmethanamine Hydrochloride exemplifies the importance of structural diversity in drug discovery. By leveraging the unique properties of heterocyclic compounds like pyrazole derivatives, scientists can identify novel therapeutic agents that address unmet medical needs.

The future prospects for this compound are promising, given its structural complexity and potential biological activity. Continued research will be essential to fully understand its pharmacological properties and therapeutic potential. As more data becomes available, it is expected that N-methyl-1-3-(1H-pyrazol-1-y]phenylmethanamine Hydrochloride will emerge as a significant player in the pharmaceutical landscape.

• 368870-03-5((4-(1H-Pyrazol-1-yl)phenyl)methanamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)